Азтреонам: фармакологические свойства и опыт клинического применения антибиотика-монобактама


Муконин А.А.

ГОУ ВПО“Смоленская государственная медицинская академия” Росздрава, Смоленск
Азтреонам – антибиотик-монобактам, обладающий селективным бактерицидным действием в отношении аэробных грамотрицательных бактерий. Спектр активности включает такие проблемные возбудители, как Pseudomonas aeruginosa и Klebsiella spp. Характерной особенностью является синергизм действия с антибиотиками других групп. Клиническая эффективность азтреонама хорошо изучена. Монобактам с успехом применялся и применяется для лечения среднетяжелых и тяжелых грамотрицательных инфекций самых различных локализаций, в т. ч. инфекций ЦНС, дыхательных путей, брюшной полости, почек и мочевыводящих путей, мягких тканей, фебрильной нейтропении и др. Особо подчеркиваются возможность применения азтреонама у пациентов с аллергией на другие ?-лактамы (пенициллины, цефалоспорины), а также хорошая переносимость терапии взрослыми и детьми с минимальным риском развития побочных лекарственных реакций. С 2009 г. азтреонам под торговым наименованием Азтреабол доступен в России.

Литература


1. Georgopapadakou NH, Liu FY. Penicillin binding proteins in bacteria. Antimicrob. Agents Chemother 1980;18:148–157.


2. Swabb EA. Review of the clinical pharmacology of the monobactam antibiotic aztreonam. Am J Med 1985;78(2):11–18.


3. Jacobus N, Ferreira M, Barza M. In Vitro Activity of Azthreonam, a monobactam antibiotic. Antimicrob Agent Chemother 1982;4:832–38.


4. Wise R, Andrews JM, Hancox J. SQ 26,766, a novel beta-lactam: an in vitro comparison with other antimicrobial agents. J Antimicrob Chemother 1981;(E):39–47.


5. Sisson TL, Jungbluth GL, Hopkins NK. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol 1999;39(12):1277–82.


6. Stutman HR, Welch DF, Scribner RK, et al.In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients. Antimicrob Agents Chemother 1984;25(2):212–15.


7. Buesing MA, Jorgensen JH. In vitro activity of aztreonam in combination with newer betalactams and amikacin against multiply resistant gram-negative bacilli. Antimicrob Agents Chemother 1984;25(2):283–85.


8. Greenberg RN, Bollinger M, Compton J. Synergistic activity of amikacin with aztreonam against Pseudomonas aeruginosa and other gram-negative organisms.Clin Ther 1986;8(3):354–58.


9. Tumah H, Velonaki A, Michalitsianos D, et al. In vitro effect of combinations of netilmicin with aztreonam against Pseudomonas aeruginosa. Chemioterapia 1987;6(2):128–29.


10. Chen YH, Peng CF, Lu P, et al. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa. Kaohsiung J Med Sci 2004;20(6):261–67.


11. Critchley IA, Sahm DF, Kelly LJ, et al.A. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli. Chemotherapy 2003;49(1–2):44–8.


12. Chow AW, Wong J, Bartlett KH. Synergistic interactions of ciprofloxacin and extended spectrum beta-lactams or aminoglycosides against Acinetobacter calcoaceticus ss. anitratus. Diagn Microbiol Infect Dis 1988; 9(4):213–17.


13. Just HM, Phillips E, Bassler M, Daschner FD. Combination effect of azthreonam with four aminoglycosides on nosocomial grampositive cocci and non-fermenting gramnegative bacteria. Eur J Clin Microbiol. 1982; 1(6):371–74.


14. Zinner SH, Ampel NM, Moon-McDermott L, et al. Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother 1982;(22):133.


15. Reeves DS, Bywater MJ, Holt HA. Antibacterial activity of the monobactam SQ 26,776 against antibiotic resistant enterobacteria, including Serratia spp. J Antimicrob Chemother1981;8(E):57–68.


16. Swabb EA, Sugerman A, et al. MultipleDose Pharmacokinetics of the Monobactam Azthreonam (SQ 26,776) in Healthy Subjects . Antimicrob. Agents Chemother 1983;23(1):125–32.


17. Swabb EA, Sugerman AA, Platt TB, et al. Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother 1982;21(6):944–49.


18. Wise R, Dyas A, Hegarty A, et al. Pharmacokinetics and tissue penetration of azthreonam. Antimicrob Agents Chemother 1982;22(6):969–71.


19. Swabb EA, Singhvi S, et al. Metabolism and рharmacokinetics of аztreonam in нealthy subjects. Antimicrob. Agents Chemother 1983;24(3):394–400.


20. Creasey WA, Platt TB, Frantz M, et al. Pharmacokinetics of aztreonam in elderly male volunteers. Br J Clin Pharmacol 1985;19(2):233–37.


21. Naber KG, Dette GA, Kees F, et al. Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections. J Antimicrob Chemother 1986;17(4):517–27.


22. Cuzzolin L, Fanos V, Zambreri D, et al. Pharmacokinetics and renal tolerance of aztreonam in premature infants. Antimicrob Agents Chemother 1991;35(9):1726–28.


23. Mattie H. Clinical pharmacokinetics of aztreonam. An update. Clin Pharmacokinet 1994;26(2):99–106.


24. Duma RJ, Berry AJ, Smith SM, et al. Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges. Antimicrob Agents Chemother 1984;26(5):730–33.


25. Okada T, Furukawa S. Clinical evaluation on aztreonam in pediatric field and fundamental study on its penetration into cerebrospinal fluid. Jpn J Antibiot 1985;38(11):3323–33.


26. Beam TR Jr, Galask RP, Friedhoff LT, et al. Aztreonam concentrations in human tissues obtained during thoracic and gynecologic surgery. Antimicrob Agents Chemother 1986;30(3):505–07.


27. Winslade NE, Smith IL, Simons GW, et al. Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis. Rev Infect Dis 1985;7(4):716–23.


28. Youngs DJ, Burdon DW, Keighley MR. The penetration of aztreonam, a monobactam antibiotic, into intra-abdominal abscesses. J Antimicrob Chemother 1989;24(3):425–29.


29. Mosley JG, Chaudhuri AK, Desai AL, et al. The distribution of aztreonam in serum, bile, skin and subcutaneous tissues in patients undergoing cholecystectomy. J Hosp Infect 1990;15(4):389–92.


30. Condon RE, Friedhoff LT, Edmiston CE, et al. Aztreonam concentration in abdominal tissues and bile. Antimicrob Agents Chemother 1986;29(6):1101–03.


31. MacLeod CM, Bartley EA, Galante JO, et al. Aztreonam penetration into synovial fluid and bone. Antimicrob Agents Chemother 1986;29(4):710–12.


32. Berthelot G, Bergogne-Berezin E, Vernant D, et al. Diffusion of aztreonam in the tissues and biological fluids of the female genital tract. Pathol Biol 1986;34(5):339–41.


33. Ito K, Hirose R, Tamaya T, et al. Pharmacokinetic and clinical studies on aztreonam in the perinatal period. Jpn J Antibiot 1990;43(4):719–26.


34. McKindley DS, Boucher BA, Hess MM, et al. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy. 1996;16(5):924–31.


35. Friedrich LV, White RL, Kays MB, et al. 3rd. Aztreonam pharmacokinetics in burn patients. Antimicrob Agents Chemother 1991; 35(1):57–61.


36. Smith G, Bunney RG, Farrell ID, et al. The use of aztreonam in serious gram-negative infections. J Antimicrob Chemother. 1988;21(2):233–41.


37. Norrby SR. Clinical experience with aztreonam in Europe: a summary of studies in Belgium, England, Finland, Ireland, the Netherlands, Norway, Portugal, and Sweden. Rev Infect Dis 1985;7(4):836–39.


38. Henry SA, Bendush CB. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. Am J Med 1985;78(2A):57–64.


39. Cristiano P, Iovene MR, Paradisi F. Aztreonam in the therapy of nosocomial infections in patients with impaired host defenses. Chemioterapia 1985;4(2):182–85.


40. DeMaria A Jr, Treadwell TL, Saunders CA, et al. Randomized clinical trial of aztreonam and aminoglycoside antibiotics in the treatment of serious infections caused by gram-negative bacilli. Antimicrob Agents Chemother 1989;33(8):1137–43.


41. Lentnek AL, Williams RR. Aztreonam in the treatment of gram-negative bacterial meningitis. Rev Infect Dis 1991;13(7):586–90.


42. Schentag JJ, Vari AJ, Winslade NE, et al. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med 1985;78(2A):34–41.


43. Swabb EA, Cone CO, Muir JG. Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections. Rev Infect Dis 1985;7(4):675–78.


44. Torres A, de Celis R, Rabinad E, et al. Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime. Chemotherapy 1989;35(1):15–24.


45. Polk HC Jr, Livingston DH, Fry DE, et al. Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial. Arch Surg 1997;132(10):1086–92


46. Raad I, Hachem R, Hanna H, et al. Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study. Ann Surg Oncol 2001;8(2):179–86.


47. Bjornson HS, Ramirez-Ronda C, Saavedra S, et al. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections. Clin Ther 1993;15(1):65–78.


48. Shimokata K, Totani Y, Morishita M, et al. Clinical study of aztreonam on respiratory tract infections caused by gram-negative pathogens. Jpn J Antibiot 1985;38(11):3415–33.


49. Cox CE. Aztreonam therapy for complicated urinary tract infections caused by multidrugresistant bacteria. Rev Infect Dis 1985; 7(4):767–71.


50. Guibert J, Acar JF, Miegi M. Clinical evaluation of azthreonam in severe urinary tract infections. Pathol Biol 1984;32(5):446–49.


51. Childs SJ. Aztreonam in the treatment of urinary tract infection. Am J Med 1985;78(2A):44–6.


52. Swabb EA, Jenkins SA, Muir JG. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections. Rev Infect Dis 1985;7(4):772–77.


53. Martelli A, Cortecchia V, Ventriglia L. Aztreonam in the treatment of urinary tract infections: a multicenter trial. Chemotherapy 1989;35(1):8–14.


54. Puppo P, Germinale F, De Rose AF. Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients. Clin Ter 1989;129(2):113–21.


55. Dodson MG. Optimum therapy for acute pelvic inflammatory disease. Drugs. 1990; 39(4):511–22.


56. Dodson MG, Faro S. The polymicrobial etiology of acute pelvic inflammatory disease and treatment regimens. Rev Infect Dis. 1985;7(4):696–702.


57. Birolini D, Moraes MF, de Souza OS. Aztreonam plus clindamycin vs. tobramycin plus clindamycin for the treatment of intraabdominal infections. Rev Infect Dis 1985;7(4):724–28.


58. Williams RR, Hotchkin D. Aztreonam plus clindamycin versus tobramycin plus clindamycin in the treatment of intraabdominal infections. Rev Infect Dis. 1991;13(7):629–33.


59. de Groot HG, Hustinx PA, Lampe AS, et al. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1993;32(3):491–500.


60. Sawyer RG, Adams RB, Pruett TL. Aztreonam vs. gentamicin in experimental peritonitis and intra-abdominal abscess formation. Am Surg 1994;60(11):849–53.


61. Fabian TC, Hess MM, Croce MA, et al. Superiority of aztreonam/clindamycin compared with gentamicin/clindamycin in patients with penetrating abdominal trauma. Am J Surg 1994;167(3):291–96.


62. Pedretti G, Magnani G. Evaluation of the clinical effectiveness of aztreonam in gram-negative infections of the biliary tract. G Ital Chemioter. 1988;35(1–3):45–8.


63. Berne TV, Yellin AE, Appleman MD, et al. Surgically treated gangrenous or perforated appendicitis. A comparison of aztreonam and clindamycin versus gentamicin and clindamycin. Ann Surg 1987;205(2):133–37.


64. Ariza J, Gudiol F, Dolz C, et al. Evaluation of aztreonam in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatology 1986;6(5):906–10.


65. Holzheimer RG, Dralle H. Antibiotic therapy in intraabdominal infections: a review of randomized clinical trial. Eur J Med Res 2001;6:277–91.


66. Nikolaidis P, Dombros N, Alexiou P, et al. Pharmacokinetics of aztreonam administered i.p. in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1989; 9(1):57–9.


67. Brown J, Altmann P, Cunningham J, et al. Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis. J Antimicrob Chemother. 1990;25(1):141–47.


68. Dratwa M, Glupczynski Y, Lameire N, et al. Treatment of gram-negative peritonitis with aztreonam in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis 1991;13(7):645–47.


69. Rabinad E, Bosch-Perez A. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients. Chemotherapy 1989;35(1):1–7.


70. Colardyn F, Gala JL, Verschraegen G, et al. Infections in patients in intensive care units: can the combination of a monobactam and a penicillin replace the classic combination of a beta-lactam agent and an aminoglycoside? Rev Infect Dis 1991;13(7):640–44.


71. Takemoto Y, Kanamaru A, Nagai K, et al. Randomized trial of combination antibiotic therapy in patients with hematological disorders. Hanshin Study Group of Hematopoietic Disorders and Infection. Jpn J Antibiot. 1990; 43(1):63–9.


72. Spencer RC, Taylor AK, Winfield DA. A comparative efficacy and safety study of teicoplanin plus aztreonam versus gentamicin plus piperacillin in haematology oncology patients with clinically diagnosed septicaemia. Br J Haematol 1990;76(2):30–4.


73. Pribyl C, Salzer R, Beskin J, et al. Aztreonam in the treatment of serious orthopedic infections. Am J Med. 1985;78(2A):51–6.


74. Simons WJ, Lee TJ. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli. Rev Infect Dis 1985; 7(4):783–88.


75. Conrad DA, Williams RR, Couchman TL, et al. Efficacy of aztreonam in the treatment of skeletal infections due to Pseudomonas aeruginosa. Rev Infect Dis 1991;13(7):634–39.


76. Brogden RN, Heel RC. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986; 31(2):96–130.


77. Cone LA, Woodard DR. Aztreonam therapy for serious gram-negative bacillary infections. Rev Infect Dis 1985;7(4):794–802.


78. Mohanty KC, Deighton R, Strachan RG. Single intramuscular injection of aztreonam in the treatment of uncomplicated gonorrhoea in women. Curr Med Res Opin 1987; 10(9):634–37.


79. Gottlieb A, Mills J. Effectiveness of aztreonam for the treatment of gonorrhea. Antimicrob Agents Chemother. 1985;27(2):270–71.


80. Stoberl C, Poitschek C, Soltz-Szots J. Aztreonam, a new approach in the therapy of gonorrhea. Wien Klin Wochenschr. 1991;103(9):271–73.


81. Schaad UB, Wedgwood-Krucko J, Guenin K, et al. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1989;8(10):858–65.


82. Jensen T, Pedersen SS, Hoiby N, et al. Safety of aztreonam in patients with cystic fibrosis and allergy to beta-lactam antibiotics. Rev Infect Dis 1991;13(7):594–97.


83. Millar MR, Inglis T, Ewing R, et al. Doubleblind study comparing aztreonam with placebo for prophylaxis of infection following prostatic surgery. Br J Urol 1987;60(4): 345–48.


84. Mozzillo N, Dionigi R, Ventriglia L. Multicenter study of aztreonam in the prophylaxis of colorectal, gynecologic and urologic surgery. Chemotherapy 1989;35(1):58–71.


85. Romanelli G, Giustina A, Cravarezza P, et al. A single dose of aztreonam in the prevention of urinary tract infections in elderly catheterized patients. J Chemother 1990;2(3):178–81.


86. Dionigi R, Mozzillo N, Ventriglia L. Comparative multicenter study on efficacy and safety of aztreonam and gentamicin in prophylaxis of high-risk colorectal surgery. J Chemother 1989;1(2):22–7.


87. Rodolico G, Puleo S, Blandino G, et al. Aztreonam versus gentamicin for short-term prophylaxis in biliary and gastric surgery. Rev Infect Dis 1991;13(7):616–20.


88. Mangioni C, Bianchi L, Bolis PF, et al. Multicenter trial of prophylaxis with clindamycin plus aztreonam or cefotaxime in gynecologic surgery. Rev Infect Dis 1991;13(7):621–25.


89. Rusconi F, Assael BM, Boccazzi A, et al. Aztreonam in the treatment of severe urinary tract infections in pediatric patients. Antimicrob Agents Chemother 1986;30(2):310–14.


90. Sunakawa K, Saito N, Ishizuka Y, et al. Fundamental and clinical studies on aztreonam in pediatrics. Jpn J Antibiot 1985; 38(11):3230–38.


91. Umana MA, Odio CM, Castro E, et al. Evaluation of aztreonam and ampicillin vs. amikacin and ampicillin for treatment of neonatal bacterial infections. Pediatr Infect Dis J 1990; 9(3):175–80.


92. Motohiro T, Kawakami A, Tanaka K, et al. Basic and clinical trials of aztreonam in the field of pediatrics. Jpn J Antibiot 1985; 38(11):3358–77.


93. Hirotsu T, Akatsuka J, Hoshi Y, et al. Clinical evaluation of aztreonam for infections accompanying febrile neutropenic children with hematologic disorders and solid tumors. A cooperative study. Jpn J Antibiot 1990;43(12):2069–77.


94. Saxon A, Hassner A, Swabb EA, et al. Lack of crossreactivity between aztreonam , a monobactam antibiotic, and penicillin in penicillin-allergic subjects. J Infect Dis 1984;149(1):16–22.


95. Moore RD, Lerner SA, Levine DP. Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill nonneutropenic patients. J Infect Dis 1992;165(4):683–88.


96. Chimura T, Satou S, Funayama T, et al. Clinical effect of the combined use of aztreonam, amikacin and clindamycin in infectious disease in obstetrics and gynecology. Jpn J Antibiot 1991;44(3):337–44.


Похожие статьи


Бионика Медиа